Special Issue "Targeting the β-Catenin/Wnt Signaling for Cancer Therapy"
Deadline for manuscript submissions: 30 October 2023 | Viewed by 1033
Interests: protein kinase Cα; tumor suppressor; nanovector; SOX9 transcription factor; colorectal cancer; wnt/beta-catenin signaling; therapeutic peptides
Special Issues, Collections and Topics in MDPI journals
The Wnt signalling pathway plays a critical role in cell proliferation, migration, polarity and self-renewal at all stages of life, from early development during embryonic stages to adult tissue homeostasis. Consequently, aberrant and disarrayed Wnt signalling is observed in the majority of cancers, and therefore, Wnt signalling components are attractive therapeutic targets when considering the treatment of various cancers. Mutation-induced activation of the Wnt/β-catenin pathway has also been identified as a frequent driver of human cancers, thus opening up exciting new avenues of research for cancer treatment. Based on these observations, novel strategies have been proposed and new drugs have been developed to block the interaction of extracellular and intracellular deregulated molecules at the transcriptional as well as translational levels so that downstream activation of the target genes is prevented. Natural antagonists of the Wnt pathway, such as secreted frizzled-related proteins (SFRPs), Dkk, ligand–receptor complexes, etc., were also made use of to trigger apoptosis in cancer cells. Studies on repurposing existing drugs have shown that nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce the risk of developing colorectal cancer by lowering the levels of nuclear β-catenin and triggering its degradation. These recent developments in this field and the concomitant understanding of the Wnt/B-catenin signaling pathways have kindled new-found hope for cancer treatment. This Special Issue, entitled "Targeting β-catenin/Wnt Signalling for Cancer Therapy", aims to sum up and highlight the latest fundamental, clinical and conceptual developments in this field. We sincerely hope that it will provide an accessible reference for furthering research in cancer therapy.
Dr. Corinne Prévostel
Dr. Lekha Dinesh Kumar
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.